Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 1/20 | 0.53 |
| ▸ | F10 | P00742 | 2/20 | 0.43 |
| ▸ | PTPRC | P08575 | 1/20 | 0.39 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | PTPRB | P23467 | 1/20 | 0.39 |
| ▸ | PTPRE | P23469 | 1/20 | 0.39 |
| ▸ | FABP4 | P15090 | 11/20 | 0.34 |
| ▸ | FABP5 | Q01469 | 11/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | CHKA | P35790 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL208908 | 0.98 | PDK1 (0.51) | PDK1F10PTPRCPTPN2PTPN1 | |
| Lithium Ion SCHEMBL208909 | 0.83 | PDK1 (0.50) | PDK1F10PTPRCPTPN2PTPN1 | |
| SCHEMBL15653322 | 0.74 | RAB9A (0.49) | PDK1 | |
| SCHEMBL8003326 | 0.74 | PDK1 (0.47) | PDK1 | |
| SCHEMBL740899 | 0.72 | PDK1 (0.61) | PDK1F10CHKA | |
| SCHEMBL743161 | 0.71 | PDK1 (0.59) | PDK1CHKA | |
| SCHEMBL2667265 | 0.71 | PDK1 (0.59) | PDK1FABP4FABP5 | |
| SCHEMBL5544815 | 0.70 | PTPN1 (0.46) | PDK1PTPN1 | |
| Hydrochloric Acid SCHEMBL3580520 | 0.69 | PDK1 (0.58) | PDK1CHKA | |
| SCHEMBL3602432 | 0.69 | HDAC2 (0.46) | F10PTPRCPTPN2PTPN1CHKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1405852-B9 | DIAMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2013-03-27 | — | — | EP | disclosed |
| US-20110312990-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
| US-7935824-B2 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2011-05-03 | — | — | US | disclosed |
| US-20110077266-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-31 | — | — | US | disclosed |
| US-20100099660-A1 | METHOD FOR TREATING THROMBOSIS OR EMBOLISM AND RELATED DISEASES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
| US-20100093785-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20090281074-A1 | DRUG COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING THROMBOSIS OR EMBOLISM | DAIICHI PHARMACEUTICAL CO., LTD (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090270446-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090227789-A1 | ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-09-10 | — | — | US | disclosed |
| US-7576135-B2 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-08-18 | — | — | US | disclosed |
| US-7365205-B2 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-04-29 | — | — | US | disclosed |
| US-7342014-B2 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-03-11 | — | — | US | disclosed |
| US-20080015215-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-01-17 | — | — | US | disclosed |
| US-20070129371-A1 | Novel ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-06-07 | — | — | US | disclosed |
| US-7192968-B2 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-20 | — | — | US | disclosed |
| US-6747023-B1 | INHIBITORS FOR ACTIVATED COAGULATION FACTOR X, COAGULATION SUPPRESSORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-08 | — | — | US | disclosed |
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1104754-A1 | NOVEL SULFONYL DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-06-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129371-A1 | Novel ethylenediamine derivatives | C1R, C9, C1S | PDK1 1414/4885F10 238/4885PTPRC 4455/4885 |
| US-20090270446-A1 | DIAMINE DERIVATIVES | F2, TFPI, F3 | PDK1 317/4885F10 4/4885PTPRC 1711/4885 |
| US-20100099660-A1 | METHOD FOR TREATING THROMBOSIS OR EMBOLISM AND RELATED DISEASES | F2, PLAT, MPL | PDK1 187/4885F10 152/4885PTPRC 3032/4885 |
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | F2, CYC1, SULT2A1 | PDK1 1617/4885F10 19/4885PTPRC 4294/4885 |
| US-20080015215-A1 | DIAMINE DERIVATIVES | C9, C1S, C1R | PDK1 696/4885F10 196/4885PTPRC 4833/4885 |
| US-20100093785-A1 | DIAMINE DERIVATIVES | C9, C1S, C1R | PDK1 628/4885F10 72/4885PTPRC 4808/4885 |
| US-20090281074-A1 | DRUG COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING THROMBOSIS OR EMBOLISM | C1R, C9, F2 | PDK1 753/4885F10 127/4885PTPRC 4304/4885 |
| US-20110077266-A1 | Diamine Derivatives | F2, TFPI, F3 | PDK1 317/4885F10 4/4885PTPRC 1711/4885 |
| US-20110312990-A1 | Diamine Derivatives | C9, C1S, C1R | PDK1 846/4885F10 138/4885PTPRC 4817/4885 |
| US-20090227789-A1 | ETHYLENEDIAMINE DERIVATIVES | F2, ECE1, MLLT1 | PDK1 2900/4885F10 126/4885PTPRC 3855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.